Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: IgA. Displaying page 5 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003392-22 Sponsor Protocol Number: PS0008 Start Date*: 2018-03-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety o...
    Medical condition: Moderate to severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001419-64 Sponsor Protocol Number: NOR-107 Start Date*: 2014-01-24
    Sponsor Name:Takeda Vaccines (Montana), Inc.
    Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001611-23 Sponsor Protocol Number: V260-035 Start Date*: 2012-09-28
    Sponsor Name:Merck Sharp & Dohme Corp., una filial de Merck & Co., Inc.
    Full Title: A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)
    Medical condition: Prevention of rotavirus gastroenteritis in infants and children caused by serotypes G1, G2, G3, G4, and G serotypes that contain P1A[8] (e.g., G9)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10039232 Rotavirus gastroenteritis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) FI (Completed) CZ (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004073-27 Sponsor Protocol Number: 18082A0002 Start Date*: 2019-03-13
    Sponsor Name:ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC)
    Full Title: Dupilumab impact on skin resident memory T cells
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001755-23 Sponsor Protocol Number: RD.06.SPR.18250 Start Date*: 2014-11-25
    Sponsor Name:Galderma R&D SNC
    Full Title: A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50μg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000767-27 Sponsor Protocol Number: CAIN457A2304 Start Date*: 2011-07-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to sever...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003642-17 Sponsor Protocol Number: OFM_DUPI_01 Start Date*: 2018-11-23
    Sponsor Name:Medical University Graz
    Full Title: AN EXPLORATORY STUDY TO INVESTIGATE THE BIOAVAILABILITY AND PHARMACODYNAMICS OF DUPILUMAB IN DERMAL INTERSTITIAL FLUID OF ATOPIC DER-MATITIS PATIENTS
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004294-13 Sponsor Protocol Number: RD.06.SPR.202699 Start Date*: 2020-10-05
    Sponsor Name:Galderma S.A.
    Full Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004200-65 Sponsor Protocol Number: LP0162-1325 Start Date*: 2017-06-28
    Sponsor Name:LEO Pharma A/S
    Full Title: A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidate...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004620-60 Sponsor Protocol Number: CAIN457A2324 Start Date*: 2018-06-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 ...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007160-19 Sponsor Protocol Number: CAEB071C2201 Start Date*: 2009-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) respoonse as a function of dose and treatment durat...
    Medical condition: Plaque psoriasis diagnosed for at least 12 months with or without psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) GB (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000277-12 Sponsor Protocol Number: 38518168PSO2001 Start Date*: 2015-04-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaquetype Psoriasis
    Medical condition: Moderate to severe plaque-type psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000725-28 Sponsor Protocol Number: KY1005-CT05_(DRI17366) Start Date*: 2022-01-24
    Sponsor Name:Kymab Limited
    Full Title: A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe At...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BG (Completed) HU (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-002920-23 Sponsor Protocol Number: CLS001-CO-PR-005 Start Date*: 2015-12-18
    Sponsor Name:Cutanea Life Sciences, Inc.
    Full Title: A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects ...
    Medical condition: Papulopustular Rosacea
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003801-90 Sponsor Protocol Number: EFC16460 Start Date*: 2020-02-11
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlle...
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10029263 Neurodermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) PT (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000459-35 Sponsor Protocol Number: TMB01-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Timber Pharmaceuticals, LLC
    Full Title: Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (Xlinked) or ARC...
    Medical condition: Congenital ichthyosis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001891-31 Sponsor Protocol Number: PS0010 Start Date*: 2016-10-27
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinectics, and Pharmacodynamics of Bimekizumab in Adult sub...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003426-16 Sponsor Protocol Number: PS0013 Start Date*: 2018-07-12
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adul...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001198-15 Sponsor Protocol Number: R668-AD-1334 Start Date*: 2015-01-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000752-34 Sponsor Protocol Number: DSLP-01 Start Date*: 2019-11-15
    Sponsor Name:DSLP
    Full Title: A Phase 2/3, multi-center, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the efficacy and safety of a topical rapamycin cream for the treatment of facial...
    Medical condition: Facial Angiofibromas Associated with Tuberous Sclerosis Complex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002429 Angiofibroma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073678 Juvenile angiofibroma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:02:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA